and aspirin in the treatment of rheumatic fever and their effects upon the evolution of rheumatic heart disease. Over a period of approximately a year and a half, and under closely defined diagnostic criteria, 497 children under the age of 16 were admitted to the trial in 12 centers in the United Kingdom, the United States, and Canada. They were allocated at random to one or another of the three agents under investigation and treated according to a specified plan for 6 weeks. After a further 3 weeks of detailed observation, they were followed up at defined intervals. Full details of the plan of study were given in an earlier publication.'
Two reports at 11 and at 5 years2 have been published. The first report compared the three treatment groups in detail throughout the 6 weeks of treatment, 3 succeeding weeks of observation, and at the end of a further year of follow-up. It was concluded that there was no evidence that any of the three agents resulted in uniform termination of the disease and that on each agent some patients developed fresh manifestations during treatment. Treatment with either of the hormones resulted in more prompt control of certain acute manifestations but this more rapid disappearance was balanced by a greater tendency for the acute manifestations to reappear for a limited period upon cessation of treatment. Congestive cardiac failure and pericarditis each responded similarly in all three treatment groups. Treatment with the hormones was followed by a more rapid disappearance of nodules and soft apical systolic murmurs but at the end of 1 year there was no significant difference between the three treatment groups in the status of the heart.
The second report2 at 5 years showed that, on the treatment schedule used, the prognosis had not been influenced more by one treatment than another. Moreover, the very low case fatality rate on each of the three treatments indicated that the patients had done well regardless of which therapy was given. In terms of natural history, the major factor determining the prevalence of rheumatic heart disease at 5 years was the status of the heart when treatment was begun. Cases requiring retreatment for recurrence of acute rheumatic fever had had a more severe cardiac involvement at the start of treatment. A larger proportion of these retreated cases had murmurs at 5 years.
After the publication of the 5-year report, and because information was lacking on the course of rheumatic fever and rheumatic heart disease in the modern era, it was decided to extend the follow-up period to 10 years. It was, however, not possible in this 6-to 10-year interval to perform repeated scheduled examinations as in the first 5 years. Instead, an examination of each case was to be made at a date as close as possible to the tenth anniversary of the end of the original 9-week period of treatment and observation. However, the long hiatus in follow-up after the 5-year examination greatly increased the difficulty in tracing some of the cases. Thus, while the 23 deaths now reported are those known to have occurred in the interval from start of treatment up through the tenth anniversary, the 10-year period for the examined cases had to be defined more broadly. Thus, in one center a relatively large number of cases had been examined in the eighth year, and in all centers a few cases were examined in the ninth year. The difficulty in finding other cases led to their examination in the eleventh, twelfth, or thirteenth year. The 10-year follow-up of examined cases, therefore, includes a range from the eighth to the thirteenth year with Circulation, Volume XXXII, September 1965 the large majority (60 per cent) examined in the tenth year (table 1) . Hereafter, with respect to the 347 examined cases in this report, the phrase "at 10 years" will refer to the period from 8 to 13 years inclusive. The number of deaths and the number of cases successfully followed up are given in table 2, where the cases have been divided into three major groups according to the status of the heart on admission to the trial: namely, Group A, no or questionable carditis* and no pre-existing heart disease; Group B, carditis--present but no pre-existing heart disease; and Group C, definite or question able pre-existing heart disease.
Lost Cases
One hundred and twenty-seven or approximately one quarter of the 497 cases (table 2) were not examined "at 10 years" and lacking evidence of their heart status, must be classified as "lost." The loss of cases resulted mostly from migration, induction into the Armed Forces, change of name by marriage, or lack of patient cooperation and the proportion varied widely among the research centers (from 9 to 50 per cent). Since this large case loss might bias the conclusions presented here, an attempt was made to determine whether the cases examined at 10 years could in fact be considered a representative sample of the total group.
It had been found at 1 year, when the full effect of the treatment of acute disease could be evaluated' and when there were very few lost cases, that residual murmurs were the best index of severity of disease. The proportion of cases in each cardiac category with murmurs at 1 year can therefore be used as an index to compare the relative severity of disease in the 10-year groups of examined and -The diagnostic criteria for admission to September 1965 by one or more of the following: ( 1 ) dyspnea, (2) orthopnea, (3) enlargement of the liver, (4) basal pulmonary rales, (5) increased jugular venous pressure, or (6) edema.
In the assessment of carditis as a criterion for entry to the trial, it was assumed in patients with no known pre-existing rheumatic heart disease or history of an attack of acute rheumatic fever that previous to the current illness the patient's heart was of normal size and that there were no rheumatic murmurs. In other patients observations of changes in heart size and murmurs were used in determining carditis and recorded. In total, it is unlikely that the lost cases at 10 years were a source of major bias in this follow-up report.
Number of Cases Traced Treatment

Deaths
Of the 497 children under the age of 16 who were admitted to the study and completed the prescribed course of treatment, only 19 were known to have died from rheumatic fever or rheumatic heart disease by the end of 10 years of follow-up* (table 2). One of these deaths occurred shortly after the end of treatment and 4 more within the first year of follow-up. There was 1 death in the third year followed by 4 in the fourth year and 4 in the fifth year. Only 5 additional deaths from rheumatic fever or rheumatic heart disease occurred in the sixth to tenth years of follow-up; 1 each in the sixth, seventh, and ninth years and 2 in the tenth year. Among the 238 females admitted to the study, there were 10 deaths (4 per cent) and among the 259 males there were 9 deaths (3 per cent of rheumatic fever and/ or rheumatic heart disease. Division by treatment showed 10 among the 162 ACTH cases (6 per cent), 3 among 167 cortisone (2 per cent), and 6 among 168 aspirin cases (4 per cent) t Death from rheumatic fever and rheumatic heart disease has been distinctly related to the cardiac status at the start of treatment. Thus, there were no deaths in the 117 Group *One child given cortisone who died 20 hours after the start of treatment is not included in the 497 children or the 19 deaths. With this single exception, all the patients survived this course of treatment. The death rates following these courses can therefore be compared without the introduction of any bias due to the incidence of deaths during treatment.
tFour additional deaths have been reported since the tenth year, all from rheumatic fever and rheumatic heart disease: 1 in the eleventh year (Group B male with failure and/or pericarditis treated with aspirin); 2 in the twelfth year (one Group B male with failure and/or pericarditis treated with cortisone and a Group C female with failure and/or pericarditis treated with cortisone) and 1 in the thirteenth year (a Group B female treated with ACTH). There were more deaths from rheumatic fever or rheumatic heart disease among those whose disease was 6 weeks or more in duration when treatment was started (10 of 104 or 10 per cent) than among those treated within 6 weeks of onset (9 of 393 or 2 per cent). This difference occurred entirely in the Group C cases where the death rate was 20 per cent among late treated cases as compared with 6 per cent among those in which treatment was begun during the first 6 weeks. The death rate was not significantly lower among those treated within 2 weeks of onset (5 of 255 or 2 per cent) than among those treated at 2 to 6 weeks (4 of 138 or 3 per cent).
The very low fatality rate during the first 10 years continued the trend of favorable life expectancy noted in previous reports. As previously noted" 2 many factors may be responsible for the striking decrease in the severity of the disease. It may also be observed that the fatality rate remains remarkably low even though all three agents were given in doses smaller than those currently in use.
In addition to the deaths resulting from rheumatic fever and rheumatic heart disease, there were 4 deaths (2 males and 2 females) Evolution of Rheumatic Heart Disease It was previously shown at 11 and at 5 years2 that the status of the heart on entry to the trial was the major factor in the evolution of rheumatic heart disease. Moreover, there was no evidence that treatment with any of the three therapeutic agents (ACTH, cortisone, or aspirin) led to a more favorable outcome. The analysis of the data at 10 years will therefore be based upon the cardiac status of the cases when treatment was begun. But, attention will be directed almost entirely to the cases in Groups A and B, since it is difficult to evaluate the course of Group C cases with their history of pre-existing heart disease of varying and sometimes long duration. The effect of recurrences of rheumatic fever and of other factors relevant to prognosis at 10 years will be studied. A special analysis will also be made of factors affecting the development of mitral stenosis. Finally, the relationship of the original treatment to the outcome at 10 years will be examined.
Cardiac Group A There were 117 cases with no carditis at the start of treatment (Group A). At 10 years, none had died, 80 were examined, and of 37 cases not examined 12 were known to be alive (table 2) .
Among the 80 cases examined (table 4) , only 5 (6 per cent) had any evidence of cardiac involvement at 10 years (3 with only a grade I apical systolic murmur,* 1 *In this study, the following grades were adopted for reporting apical systolic murmurs:
Grade O-No murmur, or a murmur considered to be "functional" on the basis of its apparent origin at the pulmonic area or along the left sternal border.
Grade P-Murmur apparently localized to the apical area, but so faint as not to be transmitted to or toward the axilla. The "P" murmurs were not considered indicative of carditis.
Grade I-Soft apical systolic murmur transmitted In summary, the prognosis of cases admitted with only a grade I apical systolic murmur is quite good. At 10 years, none had died, and among those examined 70 per cent had no apparent heart disease and 1 had developed mitral stenosis. In summary, the prognosis of cases admitted with apical systolic and mid-diastolic murmurs is uncertain. At 10 years, 2 had died of rheumatic fever and rheumatic heart disease, and among those examined 63 per cent had no apparent heart disease. It is of clinical interest that of the 38 cases admitted with apical systolic and mid-diastolic murmurs and followed for 10 years, only 2 had developed mitral stenosis. (table 4) , there were at 10 years 19 (68 per cent) with murmurs (1 with an apical systolic grade I murmur only; 5 with an apical systolic grade II or III murmur only; 3 with apical systolic and mid-diastolic murmurs (one with mitral stenosis); 3 with basal diastolic murmurs alone; 5 with basal diastolic and other murmurs, including two with basal systolic and apical systolic murmurs, two with basal systolic and apical systolic and middiastolic murmurs, and one with an apical mid-diastolic murmur. In addition, there was 1 with only an apical pre-systolic murmur (mitral stenosis). Finally, 1 case had subacute bacterial endocarditis at the time of examination, having had only a grade I apical systolic murmur at the last examination at 5 years ).
Of the 28 examined cases, 10 were reported as having had a retreated recurrence but in this severely ill group it is certain that some of the cases had continual rheumatic activity. Among the 10 cases with recurrence, heart murmurs were present at 10 years in 7, which is not different from the 12 cases with murmurs among the 18 cases not specifically treated for a recognized recurrence.
In this category the lost cases were less severely ill at 1 year than were those examined at 10 years. Thus, murmurs had been present at 1 year in only 2 of 7 cases not examined at 10 years in contrast with 22 of the 28 cases (79 per cent) examined at 10 years (table 3).
Even allowing for the possible loss of less severe cases, the prognosis in this most severely ill category of cases, admitted to the study Circulation, Volume XXXII, September 1965 with failure and/or pericarditis in the first attack of rheumatic fever, remains very serious. At 10 years, 1 had died* and among those examined only about one third had no apparent heart disease and two had developed mitral stenosis.
Recurrences in Groups A and B. The study plan specified that all cases were to receive daily prophylaxis with sulfadiazine after initial eradication of the streptococcus with a 10-day course of penicillin. Nevertheless, some recurrences did occur. It is, however, not possible to come to any conclusions as to the effectiveness of prophylaxis, since this investigation was not designed to evaluate it and the records do not include the necessary detailed information on the faithfulness with which the regimen was followed. It is, however, clear that in many cases, particularly those not seen between the 5-and 10-year examinations, prophylaxis was discontinued.
For analytical purposes, recurrences were defined as the appearance after an interval of 3 months of freedom from rheumatic activity, of manifestations that would have originally qualified the patient for admission to the trial. An analysis was made of all cases retreated for such a recurrence, but it is more informative to limit attention to cases in the cardiac Groups A and B. Many cases in Group C had continual rheumatic activity, making recurrence impossible to identify.
In Groups A and B there were, excluding recurrences of pure chorea, at least one or more retreated recurrences in 37 (14 per cent) of the 268 cases examined at 10 years (table  4) . Furthermore, these 37 cases were divided almost exactly among the three treatment groups, viz., 12 of 86 ACTH, 12 of 89 cortisone, and 13 of 93 aspirin cases. It is clear that the frequency of such recurrences does not bias the subsequent comparisons of the treatments used.
In the 5-year report it was noted of those with retreated recurrences that "the cardiac *After 10 years, 2 more cases in this category are known to have died from rheumatic fever and rheumatic heart disease; 1 in the eleventh, and 1 in the twelfth year.
Circulation, Volume XXXII, September 1965 status at start of treatment among these cases was on the average more severe than in the remainder of Group B cases." At 10 years on the other hand, there is no tendency for the proportion of cases retreated for recurrences to increase with severity of disease among the cases in Group A (9 in 80) and the subgroups of Group B without failure and/or pericarditis (18 in 160) ( (table 2) with preexisting definite or questionable heart disease prior to the attack which brought the case into the study (Group C). At 10 years, 16 had died (13 from rheumatic fever and rheumatic heart disease and 3 from other causes), Circulation, Volume XXXII, September 1965 This more serious prognosis for females is not apparent among the more severe cases, namely, the Group B cases with a basal diastolic and other murmurs, those with failure and/or pericarditis at start of treatment, the cases in Group C, and any category of cases in which recurrences took place. This difference in prognosis can also be seen in the disappearance of murmurs in the two sexes in cases without a history of recurrence examined at 1, 5 and 10 years (table 6) . Clearly, murmurs disappeared more rapidly in males than in females.
Thus, at 10 years, rheumatic fever in its milder grades had a worse prognosis for females than for males. Mitral stenosis in this study, as will be indicated later, was also more common among females. But, severe rheumatic fever has a serious prognosis for both sexes and the death rate for females (4 per cent) was in the same range as that for males (3 per cent).
There would appear to be a borderline relationship at 10 years between earlier treatment and a more favorable outcome (p = 0.05). There are, however, many selective factors affecting severity of disease which are involved in determining the date of admission of early and late cases to treatment centers. Since these factors cannot be evaluated, it is not possible to differentiate between this sampling effect and the effect of early treatment on the outcome of rheumatic fever. Furthermore, the relationship between early treatment and more favorable outcome occurs only among females (table 7) . This early treatment effect in females does not, however, explain the sex differences among the milder cases, since the less favorable outcome for females is also evident among the early treated cases. Thus, at 10 years, among milder cases in Group B (apical systolic murmur grade I alone, apical systolic murmur grade II or III alone, apical systolic and middiastolic murmurs, and basal diastolic murmurs alone) treated in the interval from 1 to 14 days, three of 22 males had murmurs compared with eight of 31 females.
Analysis of the remaining factors (table 7) *Expected numnbers take account of differences in the initial severity of cardiac involvement among groups being compared. They were calculated, separately for males and for females, in the following manner: The proportions of cases with murmurs at 10 years were taken separately for each of the six subgroups in Group B. These proportions were applied to the actual number of cases in each cardiac subgroup of the categories listed above to see how many in these small subgroups would have had a murmur at 10 years if they had experienced the total rate of occurrence. The "expected" numbers in the subgroups were added to get the total number expected in each category.
showed no correlation with the status of the heart at 10 years.
Mitral Stenosis
At 10 years, mitral stenosis was definitely diagnosed in 1 The dosage schedules of ACTH, cortisone, and aspirin were based on published studies and unpublished reports at the start of this study in 1950 and are presented in detail in previous reports." 2 The results among cases followed for 10 years are analyzed in terms of the cardiac groups already defined.
Looking first at Group A (table 8) , murmurs were present at the end of 10 years in 3 ( 11 per cent) of 28 ACTH cases (1 with an apical systolic murmur grade I only; 1 with an apical systolic murmur grade II only; and 1 with apical systolic grade II and pre-systolic murmurs (mitral stenosis)); in none of 26 cortisone cases and in 2 (8 per cent) of the 26 aspirin cases (both apical systolic grade I only). Moreover, 2 cases-the ACTH case with an apical systolic grade II murmur and an aspirin case with an apical systolic grade I murmur at 10 yearswere free of murmurs at 5 years and developed these murmurs during the 6-to 10-year interval following a retreated rheumatic fever recurrence. Thus, there is no significant difference in the cardiac status of Group A cases at 10 years among the three treatment groups. Among all of the examined cases at 10 years in Groups A, B, and C, mitral stenosis was diagnosed in 7 of 115 ACTH cases, 6 of 116 cortisone cases, and 5 of 116 aspirin cases. Mitral stenosis was also diagnosed among 4 of 10 ACTH, 1 of 2 cortisone, and 2 of 6 aspirin cases that died. The evolution of mitral stenosis at 10 years was therefore not affected by the agent used in the treatment of the acute disease.
In a therapeutic trial, factors existing prior to treatment and affecting outcome must be closely taken into account in any comparison of therapeutic results. In this study, three factors significantly affected outcome-the status of the heart at start of treatment (table 4), the sex of the patient (table  6) , and recurrences of rheumatic fever justifying retreatment (table 4) . Indeed, insofar as the status of the heart at start of treatment is concerned, it is abundantly clear that the range of 94 per cent down to 11 per cent with no heart disease at 10 years (table 10) is much more striking than differences reported here or ascribed elsewhere to the effects of treatment. Moreover, the large majority of the deaths (13 of 19) occurred among cases with pre-existing heart disease (Group C) and none among the cases without heart involvement at start of treatment (Group A). worsened the prognosis but did not increase the prevalence of mitral stenosis. Patients surviving an initial attack of rheumatic fever without residual heart disease do develop heart disease following a retreated recurrence. The effect of initial cardiac status on,the recurrence rate could not be determined.
7. Sex affected the outcome at 10 years. Rheumatic fever in its milder grades had a worse prognosis, and mitral stenosis was more common in females than in males.
8. These results make clear that the status of the heart iof the patients at the start of treatment, the rate of recurrence of acute rheumatic fever, and the sex of the subjects must all be taken closely into account in the evaluation of any treatment of acute rheumatic fever.
